Printed From BioPortfolio.com

OriGene Technologies Announces the Acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd, a Leading Chinese Pathology Reagent Company

 

ROCKVILLE, Md., March 12, 2012 /PRNewswire/ -- OriGene Technologies, Inc. announces the acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (ZsBio). The strategic acquisition establishes OriGene's leading position in the Chinese pathology testing market.

Headquartered in Beijing, China since 1993, ZsBio provides pathology testing products to the growing Chinese oncology diagnostic market. ZsBio has an industry leading position in the Chinese pathology testing market because of its innovative product portfolio, expertise, strong client relationships, and has established itself as a thought leader in the Chinese pathology diagnostic field. The Chinese pathology testing market has been experiencing double-digit growth annually and is one of the fast-growing segments of the Chinese diagnostic industry.

"With its leadership position in the Chinese pathology testing market, ZsBio is the ideal partner for OriGene," commented Wei-Wu He, CEO of OriGene. "ZsBio is already a leader in pathology products for cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories in China. In turn, OriGene brings to ZsBio innovative highly specific monoclonal antibodies and assays to complement and strengthen ZsBio's portfolio of products."

About OriGene Technologies

OriGene Technologies, Inc., is a biosciences company dedicated to develop gene centric innovative products and services to improve the quality of healthcare diagnostics and treatments. The Company's broadest collection of gene based products and services are important tools to accelerate the discovery of new diagnostics and drug treatments for better patient care. OriGene has one of the largest scale antibody production and highest quality process facility in the world. For more information, visit www.OriGene.com.

About Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd

ZsBio is one of the oldest pathology reagent suppliers in China offering products for the growing Chinese pathology testing market. The ZsBio team has more than 25 years of pathology experience in China. For additional information, please visit www.ZsBio.com.

 

 

SOURCE OriGene Technologies, Inc.

NEXT ARTICLE

More From BioPortfolio on "OriGene Technologies Announces the Acquisition of Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd, a Leading Chinese Pathology Reagent Company"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications